Research programme: somatropin oral - Access Pharmaceuticals

Drug Profile

Research programme: somatropin oral - Access Pharmaceuticals

Alternative Names: cobalamin-coated hGH-containing nanoparticles; CobOral™ hGH; CobOral™ somatropin

Latest Information Update: 16 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Access Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Growth disorders

Most Recent Events

  • 26 Mar 2014 No development reported - Preclinical for Growth disorders in USA (PO)
  • 30 Mar 2010 Access Pharmaceuticals and bioRASI enter into a collaborative clinical development agreement for oral formulations of injectable products
  • 20 Jan 2010 Preclinical trials in Growth disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top